Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
University of Pisa · Azienda Ospedaliera Universitaria Pisana · +21 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
264
total citations
- FWCI
- 24.65
- Percentile
- 100%
- References
- 36
Citations per year
Authors
37- CACarlotta Antoniotti
University of Pisa, Azienda Ospedaliera Universitaria Pisana
- DRDaniele Rossini
University of Pisa, Azienda Ospedaliera Universitaria Pisana
- FPFilippo Pietrantonio
Fondazione IRCCS Istituto Nazionale dei Tumori
- ACAurélie Catteau
- LSLisa Salvatore
Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic
Topics & keywords
Topics
Keywords
- Medicine
- Bevacizumab
- Atezolizumab
- FOLFIRI
- Irinotecan
- Internal medicine
- Oxaliplatin
- Colorectal cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.